Find out the answers to commonly asked questions below.
Find out the answers to commonly asked questions below.
ALECENSA is a treatment known as an ALK inhibitor that can be used to treat ALK+ NSCLC after the tumor has been removed by surgery. ALK+ NSCLC is a type of NSCLC that is caused by alterations of the ALK gene. Learn more about ALECENSA.
ALECENSA is not a traditional chemotherapy. It is a type of targeted therapy known as an oral ALK inhibitor. It works differently than chemotherapy since it is designed to target and block the abnormal ALK proteins responsible for the growth and spread of ALK+ NSCLC. This is important to know because the type of cancer you have, ALK+ NSCLC, may be treated by medications that target ALK.
You’ve likely completed surgery for your ALK+ early-stage NSCLC or are scheduled to get surgery soon. Your doctor has also likely performed a test to make sure that ALECENSA is right for you. Surgery is very important because it removes the visible tumors. Treatment after surgery, or adjuvant treatment, can help reduce the chance of cancer coming back. ALECENSA is prescribed as an adjuvant treatment. This means ALECENSA is used to help prevent your lung cancer from coming back after your tumor has been removed by surgery.
On April 18, 2024, ALECENSA received FDA approval as an adjuvant treatment for people with ALK+ NSCLC who have had their tumors removed. It has been approved for use as a treatment for people with ALK+ metastatic NSCLC (mNSCLC) since 2015. See the clinical trial results for ALECENSA as an adjuvant treatment here.
ALECENSA was studied in 257 people with early-stage (stage 1B to stage 3A) ALK+ NSCLC in the ALINA trial. In the trial, the effectiveness and safety of ALECENSA was compared with traditional chemotherapy. See clinical trial results.
One of the goals of adjuvant treatment is disease-free survival (DFS). This is a measurement of time after starting treatment during which no cancer is found. See clinical trial results for ALECENSA.
Possible serious side effects include liver problems (hepatotoxicity), lung problems, kidney problems, slow heartbeat (bradycardia), muscle pain, tenderness, and weakness (myalgia), breakdown of healthy red blood cells earlier than normal (hemolytic anemia). Find more information about these side effects and their symptoms here.
The most common side effects of ALECENSA include:
Here are some tips for managing common side effects.
These are not all of the possible side effects of ALECENSA. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Before you take ALECENSA, tell your doctor about all your medical conditions, including if you:
Tell your doctor about all the medications you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.
It’s important to take ALECENSA exactly as your doctor tells you to take it. Do not change your dose or stop taking ALECENSA unless your doctor tells you to. Follow these instructions:
Your doctor prescribed ALECENSA as adjuvant treatment, or after-surgery treatment. Because ALECENSA was prescribed to you in this setting, you should take 600 mg orally twice daily for a total of 2 years or until the disease comes back or you experience side effects that are not tolerable.
ALECENSA should be stored in the original container at or below 86° F (30° C), in a dry place away from light. If you think your medicine was exposed to extreme temperatures, please contact your pharmacy.
Yes. No matter what type of health insurance you have, and even if you have none at all, there may be some potential options available to help you afford your medicine. Find our financial assistance options here.
If you have questions or concerns about ALECENSA, your diagnosis, or your treatment, you should discuss them with your healthcare team. For additional resources:
You are not alone. Along with your healthcare team and caregivers, we are here to support you on your path forward with ALECENSA.
Criteria | ALECENSA dose modification |
---|---|
ALT or AST elevation of >5X ULN with total bilirubin ≤2X ULN | Temporarily withhold until recovery to baseline or to ≤3X ULN, then resume at reduced dose. See dose reduction schedule. |
ALT or AST elevation >3X ULN with total bilirubin elevation >2X ULN in the absence of cholestasis or hemolysis | Permanently discontinue ALECENSA. |
Total bilirubin elevation >3X ULN | Temporarily withhold until recovery to baseline or to ≤1.5X ULN, then resume at reduced dose. See dose reduction schedule. |
Any grade treatment-related ILD/pneumonitis | Permanently discontinue ALECENSA. |
Grade 3 renal impairment | Temporarily withhold until serum creatinine recovers to ≤1.5X ULN, then resume at reduced dose. See dose reduction schedule. |
Grade 4 renal impairment | Permanently discontinue ALECENSA. |
Symptomatic bradycardia | Withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at previous dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If no contributing concomitant medication is identified, or if contributing concomitant medications are not discontinued or dose modified, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. See dose reduction schedule. |
Bradycardiaa (life-threatening consequences, urgent intervention indicated) | Permanently discontinue ALECENSA if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm, with frequent monitoring as clinically indicated. Permanently discontinue ALECENSA in case of recurrence. See dose reduction schedule. |
CPK elevation of >5X ULN | Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at same dose. |
CPK elevation >10X ULN or second occurrence of CPK elevation of >5X ULN | Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at reduced dose. See dose reduction schedule. |
Hemolytic anemia | Withhold ALECENSA if hemolytic anemia is suspected. Upon resolution, resume at reduced dose or permanently discontinue. See dose reduction schedule. |
aHeart rate <60 bpm.
ALT=alanine transaminase; AST=aspartate transaminase; bpm=beats per minute; CPK=creatine phosphokinase; ILD=interstitial lung disease; ULN=upper limit of normal.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.